Gregory T. Lucier was chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion in 2014. During Mr. Lucier’s 11-year tenure at Life Technologies, he led the company from a small start-up known as Invitrogen in 2003, directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies, and then transformed the organization by 2013 into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries. Serving in his leadership role, Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his more than 25 years of strategic management experience to help champion an era of personalized medicine.
Dr. Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting edge therapeutic start-ups and has been a major part of the identifying companies with promising molecular and companion diagnostics to support personalized medicine. Present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to Sanofi-Aventis in April 2009. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego's CONNECT Foundation and the Hastings Center.
John Sage is the director of stakeholder communications at the Bill & Melinda Gates Foundation. Previously, Mr. Sage founded 6H Consulting LLC, where he supported for-profit and non-profit clients with business planning and marketing strategy services. Prior to 6H, he led Pura Vida Coffee through a decade of rapid growth, establishing the company as an early leader in the fair-trade movement while delivering economic benefits to farmers, families and coffee-growing communities. Sage is also a veteran of Microsoft and web pioneer Starwave and was recognized as an Ashoka Fellow in 2005 for his leadership in the field of social enterprise. Sage is a graduate of Stanford University and holds an MBA from Harvard Business School.
Dr. Evgeny Zaytsev is a managing partner at RMI Partners, the management company for RusnanoMedInvest. He was previously a general partner at Helix Ventures, which he co-founded to exclusively invest in novel therapeutic opportunities. Prior to Helix, Dr. Zaytsev was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. Dr. Zaytsev has been involved in more than 30 investments in biomedical companies and has been a board member of a number of companies in Silicon Valley and Russia. Dr. Zaytsev is an active business community leader, founder and the first president of US-Russia Technology Symposium at Stanford University (now Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Dr. Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. Dr. Zaytsev received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993, both from the Altai State Medical University. He earned his MBA from the Stanford Graduate School of Business in 2002.
Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc. In nearly 12 years as president, Dr. Critchfield built Myriad Genetic Laboratories into one of the world’s leading molecular diagnostics companies. Under his leadership, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was chief medical and science officer for Quest Diagnostics, Inc., overseeing medical affairs and innovation activities in its transformation from Corning Clinical Laboratories. He has also served on the faculty of three medical schools: University of Minnesota, Wayne State University, and Duke University, and was a practicing clinical pathologist with Intermountain Healthcare.